MYC and hepatocellular carcinoma: The glutamine-addiction of MYC transformed cells provides possible therapeutic opportunities and for example, pharmacologic inhibition of GLS1 has been shown to inhibit tumor progression in mouse models of MYC-driven Burkitt's lymphoma or hepatocellular carcinoma (Le et al., 2012; Xiang et al., 2015).